uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $60.8182.

Several research firms have recently weighed in on QURE. Royal Bank Of Canada reduced their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Stifel Nicolaus cut their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. The Goldman Sachs Group reduced their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. UBS Group set a $95.00 price target on uniQure in a report on Thursday, September 25th. Finally, Chardan Capital reiterated a “buy” rating and set a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th.

uniQure Stock Up 3.9%

Shares of QURE stock opened at $22.84 on Monday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock has a market cap of $1.42 billion, a PE ratio of -5.20 and a beta of 0.68. The business’s fifty day moving average is $24.77 and its 200-day moving average is $27.91. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. Equities analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 102,247 shares of company stock valued at $2,839,298. 4.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently made changes to their positions in the company. Private Trust Co. NA acquired a new position in uniQure in the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp lifted its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the third quarter worth $50,000. FNY Investment Advisers LLC grew its holdings in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.